Australian University Rankings Guide

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology (ERA Journal)

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology is an ERA accredited research journal used as part of the evaluation of the ERA research rankings.

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology issns are issn1: 1939-0041 issn2: 1939-5116.

The fields covered by Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology as part of the evaluation of Australian university research excellence are:

Medicinal and Biomolecular Chemistry Research Rankings (Sub-Field)

Biomedical Engineering Research Rankings (Sub-Field)

Nanotechnology Research Rankings (Sub-Field)

Other ERA-accredited journals supporting the evaluation of the Medicinal and Biomolecular Chemistry field include:

- Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry
- BioMolecular Concepts
- Bioconjugate Chemistry
- Carbohydrate Research
- Chemical and Pharmaceutical Bulletin
- Contrast Media and Molecular Imaging
- Current Opinion in Chemical Biology
- Drugs in R and D
- European Journal of Mass Spectrometry
- Free Radical Biology and Medicine
- International Journal of Molecular Medicine
- Journal of Computer-Aided Molecular Design
- Molecular and Cellular Probes
- Synlett: accounts and rapid communications in synthetic organic chemistry
- Vibrational Spectroscopy


ERA Research Rankings Submenu


- ERA 2018 Outcomes Research Rankings List

- ERA 2018 Research Rankings Analysis

- ERA 2018 Individual University Outcomes List

- ERA List of Research Fields Rankings

- ERA Journal Rankings 2018 List



Latest News and Updates:


- Top 10 Best Australian Universities

- Gender Balance Male-Female Ratio

- ERA 2018 Outcomes Research Rankings List

- University Bachelor Degree Completion Rates

- QS Employability Rankings Australian Universities

- ARWU World Rankings of Australian Universities

- Group of Eight (go8) World Rankings

Share This Page

  • Share on Facebook1
  • Share on Twitter2
  • Share on Linkedin3
  • Share on Reddit4